Information revealed at the 2024 AAIC conference on the ACTC-DS-led study in DS-associated Alzheimer’s disease with Lilly’s anti-amyloid drug Kisunla.
FDA issues approval for Kisunla, new Alzheimer’s drug; Down syndrome community optimistic On Tuesday, July 2, the U.S. Food and
Major pharmaceutical company announces Down syndrome population will see a clinical trial of new Alzheimer’s drug People with Down syndrome
Individuals with Down syndrome may experience decline in skills for many reasons, some of which are potentially reversible. In this
LuMind IDSC is encouraged by today’s news that the U.S. Food and Drug Administration (FDA) is requesting more time and
“Adapting prescribing criteria for amyloid‐targeted antibodies for adults with Down syndrome” published in the journal of the Alzheimer’s Association Drawing
Fact sheet about dementia and intellectual disabilities from the National Task Group on Intellectual Disabilities and Dementia Practices (NTG).Source: National
Individuals with Down syndrome (DS) are living longer than they used to. This trend has led to a heightened prevalence
At a recent Advocate Aurora Health event, Darren Gitelman, MD, Senior Medical Director of the Advocate Memory Center, presented on
In this webinar, Dr. Michael Rafii joins the National Down Syndrome Society (NDSS) to discuss the latest understanding of Alzheimer’s
